万基遗传披露未来规划：聚焦精准诊断与药物研发

Core Insights - The company Wanji Genetic disclosed its future plans during the fiscal year 2025 earnings meeting, highlighting significant growth strategies and R&D advancements [1] Performance Strategy - The company plans to increase the size of its pathology sales team by 25% in 2026, focusing on expanding its market share in rare diseases and reproductive health [2] - The biopharmaceutical services will continue to expand multi-omics platform orders [2] - In terms of drug development, the project 007 (head and neck cancer) is expected to advance to Phase III clinical trials, while project 022 (multi-organ cancer) is currently in Phase I [2] - R&D expenditures are projected to potentially double compared to 2025 [2]